文献速递神经肿瘤

CDK7与CDK9抑制干扰转录、翻译和干性并在胶质母细胞瘤中诱导细胞毒性,且与替莫唑胺敏感性无关

CDK7 and CDK9 inhibition interferes with transcription, translation, and stemness, and induces cytotoxicity in GBM irrespective of temozolomide sensitivity.
PubMed 文献 · Neuro Oncol · 2024-01-01

研究检验抑制CDK7或CDK9能否有效对抗胶质母细胞瘤且降低神经毒性;CDK7抑制剂THZ1与多种CDK9抑制剂在低纳摩尔浓度下抑制替莫唑胺敏感及耐药胶质母细胞瘤细胞与胶质瘤干细胞的活力,并在皮下与原位移植模型中抑制肿瘤生长。

要点

  • CDK7抑制剂THZ1与CDK9抑制剂在低纳摩尔浓度下抑制替莫唑胺敏感和耐药胶质母细胞瘤细胞及胶质瘤干细胞的活力。
  • 抑制剂可阻断RNA聚合酶II与p70S6K磷酸化及新生蛋白合成,并显著降低胶质瘤干细胞自我更新及Sox2、Sox9水平。
  • 皮下与原位胶质母细胞瘤移植模型中给予CDK9抑制剂明显抑制肿瘤生长。

核心结论

  • 作者认为CDK7与CDK9靶向治疗可能对替莫唑胺敏感和耐药的胶质母细胞瘤均有效。

研究设计与样本

  • 体外研究:CDK7抑制剂THZ1与CDK9抑制剂SNS032、AZD4573、NVP2、JSH150作用于胶质母细胞瘤细胞系、患者来源的替莫唑胺耐药与敏感原发肿瘤细胞及胶质瘤干细胞。
  • 采用蛋白质印迹、免疫荧光、多光谱成像和RT-PCR评估生化变化。
  • 体内在皮下与原位异种移植模型中评估疗效。

主要发现

  • CDK7和CDK9抑制剂在低纳摩尔浓度下抑制替莫唑胺敏感与耐药胶质母细胞瘤细胞及胶质瘤干细胞的活力,体内细胞毒性作用有限。
  • 抑制剂阻断RNA聚合酶II与p70S6K磷酸化及新生蛋白合成,胶质瘤干细胞自我更新显著降低,Sox2与Sox9水平相应下降。
  • TCGA数据分析显示胶质母细胞瘤中CDK7、CDK9、SOX2、SOX9和RPS6KB1表达升高;组织芯片多光谱成像显示胶质母细胞瘤较正常脑组织CDK9、Sox2、Sox9、磷酸化S6和磷酸化p70S6K水平升高。
  • RNA测序结果提示抑制剂抑制促肿瘤基因并诱导抑肿瘤基因。
  • 皮下与原位胶质母细胞瘤异种移植模型研究显示给予CDK9抑制剂明显抑制体内肿瘤生长。

临床怎么用

  • 作者在结论中提出CDK7与CDK9靶向治疗可能对替莫唑胺敏感和耐药的胶质母细胞瘤有效,原文未据此给出具体临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glioblastoma (GBM) is refractory to current treatment modalities while side effects of treatments result in neurotoxicity and cognitive impairment. Here we test the hypothesis that inhibiting CDK7 or CDK9 would effectively combat GBM with reduced neurotoxicity. METHODS: We examined the effect of a CDK7 inhibitor, THZ1, and multiple CDK9 inhibitors (SNS032, AZD4573, NVP2, and JSH150) on GBM cell lines, patient-derived temozolomide (TMZ)-resistant and responsive primary tumor cells and glioma stem cells (GSCs). Biochemical changes were assessed by western blotting, immunofluorescence, multispectral imaging, and RT-PCR. In vivo, efficacy was assessed in orthotopic and subcutaneous xenograft models. RESULTS: CDK7 and CDK9 inhibitors suppressed the viability of TMZ-responsive and resistant GBM cells and GSCs at low nanomolar concentrations, with limited cytotoxic effects in vivo. The inhibitors abrogated RNA Pol II and p70S6K phosphorylation and nascent protein synthesis. Furthermore, the self-renewal of GSCs was significantly reduced with a corresponding reduction in Sox2 and Sox9 levels. Analysis of TCGA data showed increased expression of CDK7, CDK9, SOX2, SOX9, and RPS6KB1 in GBM; supporting this, multispectral imaging of a TMA revealed increased levels of CDK9, Sox2, Sox9, phospho-S6, and phospho-p70S6K in GBM compared to normal brains. RNA-Seq results suggested that inhibitors suppressed tumor-promoting genes while inducing tumor-suppressive genes. Furthermore, the studies conducted on subcutaneous and orthotopic GBM tumor xenograft models showed that administration of CDK9 inhibitors markedly suppressed tumor growth in vivo. CONCLUSIONS: Our results suggest that CDK7 and CDK9 targeted therapies may be effective against TMZ-sensitive and resistant GBM.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Bhutada I, Khambati F, Cheng SY, et al. CDK7 and CDK9 inhibition interferes with transcription, translation, and stemness, and induces cytotoxicity in GBM irrespective of temozolomide sensitivity. Neuro Oncol. 2024. PMID: 37551745. doi:10.1093/neuonc/noad143

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。